



92W1615

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicants:</b>	Jonathan B. Baell, et al.	<b>Examiner:</b>	Unassigned
<b>Serial No.:</b>	10/507,925	<b>Art Unit:</b>	1615
<b>Filed:</b>	September 16, 2004	<b>Docket:</b>	18223
<b>For:</b>	THERAPEUTIC ION CHANNEL BLOCKING AGENTS AND METHODS OF USE THEREOF	<b>Dated:</b>	September 7, 2005

**Confirmation No.:** 6810

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Wulff H. et al., "Nonpeptide Bivalent Blockers of Kv1.3 Channels Based on the Benzofuran Pharmacophore", *The Physiologist*, 42(A-12), Abstract 5.67 (1999);
2. Wulff H. et al., "Nonpeptide Bivalent Blockers of Kv1.3 Channels Based on the Benzofuran Pharmacophore", *Poster Abstract 1078 from Pharmaceutical Institute, Kiel, Germany* (1999);

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 7, 2005

  
Frank S. DiGiglio

3. Beeton C. et al., "Selective Blockade of T Lymphocyte K<sup>+</sup> Channels Ameliorates Experimental Autoimmune Encephalomyelitis, a Model for Multiple Sclerosis", *Proc. Natl. Acad. Sci. USA*, 98(24):13942-13947 (2001);
4. United States Patent No. 5,494,895, dated February 27, 1996 to Garcia et al.;
5. United States Patent No. 6,051,590, dated April 18, 2000 to Bao et al.;
6. United States Patent No. 6,077,680, dated June 20, 2000 to Kem et al.;
7. PCT International Publication No. WO 97/16438, published May 9, 1997;
8. PCT International Publication No. WO 97/16437, published May 9, 1997;
9. Baell J.B. et al., "Khellinone Derivatives as Blockers of the Voltage-Gated Potassium Channel Kv1.3: Synthesis and Immunosuppressive Activity", *J. Med. Chem.*, 47:2326-2336 (2004);
10. Cianci J. et al., "Khellinone Derivatives as Blockers of the Kv1.3 Potassium Channel", *Poster Abstract for Connect 2005, Sydney, Australia*, (2005); and
11. Baell J.B. et al., "Khellinone Derivatives as Blockers of the Kv1.3 Potassium Channel", *J. Med. Chem.*, 47:2326-2336 (2004).

Reference No. 1 was cited in a Search Report dated June 26, 2003 received from the Australian Patent Office. The relevance of reference no. 1 has been described in the Search Report. The relevance of above-identified reference nos. 1, 3-8 has been described in the specification. Applicants are submitting copies of above-cited reference nos. 1-3, 7-11, together with a copy of the Search Report. In accordance with the waiver of 37 C.F.R. § 1.98 (a)(2)(i) in effect as of June 30, 2003, applicants are not required to submit copies of the above-cited U.S. Patent references.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Frank S. DiGiglio". The signature is stylized with a large, looped "F" and "D".

Frank S. DiGiglio  
Registration No. 31,346

Scully, Scott, Murphy & Presser  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
(516) 742-4343  
YL:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(REV. 7-80) PATENT AND TRADEMARK OFFICE**LIST OF PRIOR ART  
CITED BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No. (Optional)

18223

Application Number

10/507,925

Applicant(s)

Jonathan B. Baell, et al.

Filing Date

September 16, 2004

Group Art Unit

1615

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA	5,494,895	2/27/96	Garcia et al.			
	AB	6,051,590	4/18/00	Bao et al.			
	AC	6,077,680	6/20/00	Kem et al.			

**FOREIGN PATENT DOCUMENTS**

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 97/16438	5/9/97	PCT			✓	
		WO 97/16437	5/9/97	PCT			✓	


**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

		Wulff H. et al., "Nonpeptide Bivalent Blockers of Kv1.3 Channels Based on the Benzofuran Pharmacophore", <i>The Physiologist</i> , 42(A-12), Abstract 5.67 (1999)
		Wulff H. et al., "Nonpeptide Bivalent Blockers of Kv1.3 Channels Based on the Benzofuran Pharmacophore", <i>Poster Abstract 1078 from Pharmaceutical Institute, Kiel, Germany</i> (1999)
		Beeton C. et al., "Selective Blockade of T Lymphocyte K <sup>+</sup> Channels Ameliorates Experimental Autoimmune Encephalomyelitis, a Model for Multiple Sclerosis", <i>Proc. Natl. Acad. Sci. USA</i> , 98(24):13942-13947 (2001)
		Baell J.B. et al., "Khellinone Derivatives as Blockers of the Voltage-Gated Potassium Channel Kv1.3: Synthesis and Immunosuppressive Activity", <i>J. Med. Chem.</i> , 47:2326-2336 (2004)
		Cianci J. et al., "Khellinone Derivatives as Blockers of the Kv1.3 Potassium Channel", <i>Poster Abstract for Connect 2005, Sydney, Australia</i> , (2005)
		Baell J.B. et al., "Khellinone Derivatives as Blockers of the Kv1.3 Potassium Channel", <i>J. Med. Chem.</i> , 47:2326-2336 (2004)

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
**18223**

In Re Application Of: **Jonathan B. Baell, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/507,925	September 16, 2004	Unassigned	23389	1615	6810

Title:

**THERAPEUTIC ION CHANNEL BLOCKING AGENTS AND METHODS OF USE THEREOF**

Address to:  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.


**37 CFR 1.97(c)**

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

**OR**

☐ the fee set forth in 37 CFR 1.17(p).



**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
18223

In Re Application of: **Jonathan B. Baell, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/507,925	September 16, 2004	Unassigned	23389	1615	6810

Title:

**THERAPEUTIC ION CHANNEL BLOCKING AGENTS AND METHODS OF USE THEREOF**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____ (Date) _____ Signature _____	
Typed or Printed Name of Person Signing Certificate	

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on <u>September 7, 2005</u> (Date) _____ Signature of Person Mailing Correspondence <u>Frank S. DiGiglio</u>	
Typed or Printed Name of Person Mailing Certificate	

**\*This certificate may only be used if paying by deposit account.**

Frank S. DiGiglio  
Signature

Dated: **September 7, 2005**

**Frank S. DiGiglio**  
Registration No. 31,346  
Scully, Scott, Murphy & Presser  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
516-743-4343

CC: